Navigation Links
Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months
Date:7/1/2010

ents were safely transitioned to VPRIV (15-60U/kg EOW) from the same number of units of imiglucerase. Clinical measures of disease remained stable over 12 months.

TKT-034 Results Highlights Include:

  • No patients developed IgG antibodies to VPRIV, including 3 patients who tested positive for anti-imiglucerase antibodies at screening.
  • Hemoglobin concentrations, platelet counts, and liver and spleen volumes remained stable over the course of the one year study.

"We are very pleased with the opportunity to present these findings at the EWGGD, a key scientific meeting for the Gaucher community," said Ferd Massari, VP and Global Head of Clinical and Medical Affairs, Shire Human Genetic Therapies. "The data presented underscore the long term safety and efficacy of VPRIV for treatment naïve Gaucher patients, as well as for patients who switched from imiglucerase to VPRIV. Moreover, they demonstrate that VPRIV may offer benefits regarding the achievement of therapeutic goals, including improvements in bone parameters."

About VPRIV

VPRIV is Shire's enzyme replacement therapy for type 1 Gaucher disease. VPRIV is made using Shire's gene-activation technology, in a human cell line. The enzyme produced has the exact human amino acid sequence and has a human glycosylation pattern.

VPRIV was approved by the US FDA as a long-term enzyme replacement therapy for adult and pediatric patients with type 1 Gaucher disease on February 26, 2010. On June 25, 2010, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion on the marketing authorisation for VPRIV for the treatment of type 1 Gaucher disease.


'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... NEW YORK , March 5, 2015 /PRNewswire/ ... evolving set of regulations, Ethics & Compliance professionals ... according to a new survey issued today by ... services and education. An overwhelming majority of respondents ... far the most important component of E&C training ...
(Date:3/5/2015)... , March 5, 2015 CANTEL MEDICAL CORP. ... its second quarter ended January 31, 2015 on Thursday, March ... to discuss the results at 11:00 AM ET. ... approximately 5 to 10 minutes before the beginning of the ... of the call will be available from Thursday, March 12, ...
(Date:3/5/2015)... 2015  Medical Diagnostic Laboratories, L.L.C., (MDL), a ... state-of-the-art, automated DNA-based molecular analyses, announces that it ... which utilizes cutting edge technology, including next- generation ... 12,000 women are diagnosed with cervical cancer in ... Human Papillomaviruses (HPV) are a group of more ...
Breaking Medicine Technology:Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3
... Loss, Non-Inferiority in Target Vessel Failure and Low Rates of MACE ... ... PARK, Ill., April 22 A study published,in today,s Journal of ... Everolimus Eluting Coronary Stent System,in patients with coronary artery disease resulted ...
... April 22 , - Summary: Using Protein ... Mode of Action of Humax- EGFr,(Zalutumumab). In This ... That,Zalutumumab Locks the EGFr Into a Very Compact ... Growth., Sidec AB announced today that together ...
Cached Medicine Technology:Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 2Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 3Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 4Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 5Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS 2
(Date:3/5/2015)... At the 7th Annual Mississippi ... addiction treatment met today in Jackson, Mississippi to listen ... Among the numerous respected speakers will be William ... role that pain medications have had in today’s opiate ... , "It is hard to believe that much of ...
(Date:3/5/2015)... 05, 2015 Califia Farms , ... at Natural Products Expo West that its popular ready-to-drink ... percent soy and dairy free. Califia Farms Vegan Protein ... and are packed with six grams of an innovative ... fiber, B vitamins and magnesium. , Protein is an ...
(Date:3/5/2015)... 2015 University of Western States ... 1904, has launched a new center of excellence ... The Northwest Center for Lifestyle and Functional Medicine ... outreach, and conduct research in the areas of ... nutrition. The center will target efforts on the ...
(Date:3/5/2015)... 05, 2015 Supply & Demand Chain ... of “Pros to Know” in the supply chain industry, ... of MEBC’s leadership team were included on this year’s ... received this award due to their hard work, their ... for meeting and resolving client needs and challenges. ...
(Date:3/5/2015)... Dr. Jonathan Glashow a board certified New ... named by Castle Connolly as a Top ... has been selected by Castle Connolly Medical Ltd. for ... care doctors in the tri-state metropolitan New York area ... carefully screens and selects doctors through a rigorous peer ...
Breaking Medicine News(10 mins):Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 2Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 3Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2
... , , , ... month that the first recipients enrolled in Medicare. Now is the time ... for all," said Dr. Jane L. Delgado, President and CEO of the National ... , , "President Obama set out in his ...
... Evidence That Criticisms Are Registering As Debate Intensifies , ... Congress works through specific health reform proposals, the July Kaiser Health Tracking Poll ... reform now, though there is some softening of support as criticisms and doubts ... been the case over the past ten months, a majority of the American ...
... 28th Annual KLOS Blood Drive Aims ... LOS ANGELES, July 22 The American Red Cross and 95.5 KLOS ... Blood Drive. The 2009 KLOS Blood Drive will run for five days, ... and classic rock fans are encouraged to donate at any of the 19 ...
... , INCLINE VILLAGE, Nev., July 22 PDL BioPharma, ... hold a conference call and webcast on Thursday, July 30 at 4:30 p.m. ... and provide a business update. The call and webcast will follow the release ... , , Conference Call Details , ...
... shows devices contain carcinogens, other toxins , WEDNESDAY, ... cigarettes, known as e-cigarettes, has shown that they ... compound used in antifreeze, U.S. health officials said ... cartridges filled with nicotine, flavorings and other chemicals. ...
... WASHINGTON, July 22 There are many provisions in ... care greatly about the freedom to choose their health care. Some of ... * Eliminates Existing Private Insurance Coverage (i.e., Eliminates Your Choice ... But Is Just Fine With You and Your Family) , ...
Cached Medicine News:Health News:Time to Get the Job Done Says Alliance President and CEO 2Health News:Majority of Public Maintains Support for Addressing Health Care Reform Now 2Health News:Majority of Public Maintains Support for Addressing Health Care Reform Now 3Health News:Majority of Public Maintains Support for Addressing Health Care Reform Now 4Health News:Majority of Public Maintains Support for Addressing Health Care Reform Now 5Health News:KLOS & Red Cross Set to Rock SoCal With Massive 5 Day Blood Drive 2Health News:KLOS & Red Cross Set to Rock SoCal With Massive 5 Day Blood Drive 3Health News:PDL BioPharma to Announce Second Quarter 2009 Financial Results and Hold Conference Call July 30, 2009 2Health News:E-Cigarettes Pose a Health Hazard, FDA Warns 2Health News:E-Cigarettes Pose a Health Hazard, FDA Warns 3Health News:Mandate for Health Insurance: Inconvenient Truths About How It Will Affect You and Your Family 2
... Ant-Cer is the newest addition ... anterior cervical plates. Ant-Cer addresses ... stabilization of the cervical spine. ... adjust settling to fit patients' ...
... Revolutions start with small things. The ... one of the trailblazers of the ... the,trend towards ever smaller access and ... operation site. ,The HiLAN XS motor ...
Relocatable frame has been designed specifically for fractionated stereotactic radiotherapy treatments. It provides a fast, non-invasive and reproducible fixation of the patient....
The unique MR-frame and its indicators are made of a highly tensile and fibre reenforced Epoxyd material....
Medicine Products: